

# ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock**

## Company



2024/05/17 22:00:02

Price

**166.42**

USD

Difference

1.26%(2.07)



## Contact Details

ABBVIE INC.

Tel: +1-847-932-7900

--

Fax: +

1 North Waukegan Road

Web: <http://www.abbvie.com>

60064-6400 North Chicago

E-mail: -

## Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023            |                        | 2022            |                        | 2021            |                        |
|--------------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                | Assets          | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| Current assets                 | 33,002,000,000  |                        | 28,463,000,000  |                        | 27,928,000,000  |                        |
| Common stock capital           |                 | 18,000,000             |                 | 18,000,000             |                 | 18,000,000             |
| Fixed assets                   | 101,709,000,000 |                        | 110,342,000,000 |                        | 118,601,000,000 |                        |
| Equity capital of a company    |                 | 10,397,000,000         |                 | 17,287,000,000         |                 | 15,436,000,000         |
| Cash and cash equivalents      | 12,814,000,000  |                        | 9,201,000,000   |                        | 9,746,000,000   |                        |
| Accrued liabilities            |                 | 1,538,000,000          |                 | 1,638,000,000          |                 | 3,153,000,000          |
| Other assets                   | -               |                        | -               |                        | -               |                        |
| Current liabilities            |                 | 37,841,000,000         |                 | 29,538,000,000         |                 | 35,194,000,000         |
| Prepayments and accrued income | -               |                        | -               |                        | -               |                        |
| Non-current liabilities        |                 | 86,473,000,000         |                 | 91,980,000,000         |                 | 95,899,000,000         |
| Different income               |                 | -                      |                 | -                      |                 | -                      |
| Other liabilities              |                 | 23,373,000,000         |                 | 21,761,000,000         |                 | 18,865,000,000         |
| Total assets                   | 134,711,000,000 | 134,711,000,000        | 138,805,000,000 | 138,805,000,000        | 146,529,000,000 | 146,529,000,000        |

## Balance notes

|                     | 2023      | 2022    | 2021    |
|---------------------|-----------|---------|---------|
| Accounting standard | US-GAAP   | US-GAAP | US-GAAP |
| Employees           | 50,000    | 50,000  | 50,000  |
| Equity ratio        | 7.75%     | 12.48%  | 10.55%  |
| Debt-equity ratio   | 1,191.08% | 701.41% | 847.55% |

## Others

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 22.03% | 12.11% | 11.09% |

# ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock**

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 54,318,000,000 | 58,054,000,000 | 56,197,000,000 |
| Net income  | 4,820,000,000  | 11,782,000,000 | 11,468,000,000 |
| EBIT  | 7,411,488,000  | 14,361,020,800 | 14,142,441,600 |
| Operating income before taxes                                 | 6,250,000,000  | 13,477,000,000 | 12,989,000,000 |
| Cash Flow   | 22,801,000,000 | 24,943,000,000 | 22,777,000,000 |
| Net interest income   | -1,820,000,000 | -2,160,000,000 | -2,410,000,000 |
| Research and development expenses                             | 7,038,000,000  | 6,487,000,000  | 6,980,000,000  |
| Income taxes  | 1,377,000,000  | 1,632,000,000  | 1,440,000,000  |
| Result from investments in subsidiaries, associates and other | 0              | 0              | 0              |
| Revenues per employee   | 997,713        | 1,066,336      | 1,032,226      |

## Board of Directors

## Members of Management Board

|                       |                               |
|-----------------------|-------------------------------|
| Robert Alpern         | Member of Board of Directors  |
| Susan Quaggin         | Member of Board of Directors  |
| Brett Hart            | Member of Board of Directors  |
| Edward Rapp           | Member of Board of Directors  |
| Frederick Waddell     | Member of Board of Directors  |
| Glenn Tilton          | Member of Board of Directors  |
| Jennifer Davis        | Member of Board of Directors  |
| Melody Meyer          | Member of Board of Directors  |
| Rebecca Roberts       | Member of Board of Directors  |
| Roxanne Austin        | Member of Board of Directors  |
| Thomas Freyman        | Member of Board of Directors  |
| William Burnside      | Member of Board of Directors  |
| Richard A. Gonzalez   | Chairman of Managing Board    |
| Azita Saleki-Gerhardt | Member of Executive Committee |
| Jeffrey R. Stewart    | Member of Executive Committee |
| Nicholas Donoghoe     | Member of Executive Committee |
| Perry C. Siatis       | Member of Executive Committee |
| Robert A. Michael     | Member of Executive Committee |
| Scott Reents          | Member of Executive Committee |
| Timothy J. Richmond   | Member of Executive Committee |